1 / 70

TRANSPLANT ID: A PRACTICAL APPROACH

TRANSPLANT ID: A PRACTICAL APPROACH. Atul Humar Transplant Infectious Diseases University of Alberta. WHATS NEW?. Changing immunosuppression Widespread prophylaxis Emerging infections Evolving infections Donor Derived infection Molecular diagnostics Host-pathogen interactions.

danniell
Download Presentation

TRANSPLANT ID: A PRACTICAL APPROACH

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. TRANSPLANT ID: A PRACTICAL APPROACH Atul Humar Transplant Infectious Diseases University of Alberta

  2. WHATS NEW? • Changing immunosuppression • Widespread prophylaxis • Emerging infections • Evolving infections • Donor Derived infection • Molecular diagnostics • Host-pathogen interactions

  3. INFECTION: BASIC PRINCIPLES • Inflammatory response attenuated by immunosup. • may abolish typical signs/symptoms • decreased sensitivity of serological, radiological tests • Efffects of established infection may be devastating • Treatment may have more toxicities • Rifampin - decrease CNI • Erythromycin, azoles increase CNI • Synergistic nephrotoxicity - aminoglycosides, AmB, high dose septra,

  4. INFECTION: BASIC PRINCIPLES • Determinants of infection • Technical issues with transplantation • Vascular anastomoses – leak, thrrombosis, stricture • Non-vascular anastomoses- leak, stricture • Net state of immunosuppression • Epidemiologic exposures

  5. Major determinants of the risk of infection INFECTIONS IN TRANSPLANTATION The net state of Immunosuppression Epidemiological exposures

  6. NET STATE OF IMMUNOSUPPRESSION • Immunosuppressive therapy: dose, duration, temporal sequence - ‘area under the curve’ • Induction therapy – especially ALG, Alemtuzimab • Mucocutaneous barrier integrity: intubation, drains, catheters, central lines • Neutropenia, lymphopenia • Viral co-infection – CMV, HCV, HIV

  7. NET STATE OF IMMUNOSUPPRESSIONCAN WE MEASURE? • Non-specific immunoassays • Intracellular ATP, biomarkers, proteomic-based technologies • Pathogen-specific immunity • ICS • IFN-g assays, • HLA tetramers • Elispot

  8. EPIDEMIOLOGICAL EXPOSURES Overlapping but distinct exposures Community – CAP, CA-MRSA, Endemic mycosis, respiratory viruses, enteric viruses Nosocomial – MRSA, aspergillus, MDR gram negatives, VRE Donor – latent or active infection Recipient – latent or active infection

  9. AN EXAMPLE OF EPIDEMIOLOGIC EXPOSURE • 61 y.o. male heart transplant 1991 • Stable immunosuppression x years • cylosporin, prednisone • 3 week history of progressive leg cellulitis, fever unresponsive to antibiotics • Intermittent confusion

  10. What was the exposure? • This patient generally will not get an OI unless some excess exposure • Exposure: • Delivery of topsoil to his home • Legs knee deep in topsoil while he was spreading it

  11. Tx ID TIMELINE: 0-1 MONTH • Post-op Infections • Technical / anastomotic related infection • nosocomial pneumonia, wound, etc • MRSA, VRE, Candida, C. difficile • Donor Derived Infection • These are rare but diagnosis can be missed • Recipient derived infection • Ongoing pneumonia • Colonization to infection • Most OI absent: exceptions include certain fungal infections, HSV, occasional others

  12. Tx ID TIMELINE 1-6 MONTH Account for CMV, PCP prophylaxis • BK viruria – viremia. BKVAN • CMV: D+/R- month 3-6; augmented immunosuppression • EBV viremia D+/R- • HCV recurrence (OLTx) • C. difficile, Fungal, mycobacterial, respiratory virus • VZV post-prophylaxis

  13. BRONCHOSCOPY: TESTS • Gram stain and culture • Fungal stain and culture • AFB smear and culture • Legionella DFA, culture • CMV shell vial culture • Respiratory viruses culture; DFA for HSV, Influenza, parainfluenza, RSV, adenovirus • stain for PCP • Cytology • Molecular testing replacing traditional testing

  14. Tx ID TIMELINE >6 MONTH • Depends on outcome: good vs. bad graft function. Tapering immunosuppression vs. ongoing high level – problems with rejection • Some patients at ongoing risk of OI despite minimal exposures • Others only get OI if significant exposure

  15. Tx ID TIMELINE >6 MONTH • Late viral infections • CMV (colitis, recurrence), BKVAN, PTLD, HCV • Community acquired infection • Respiratory virus, CA-MRSA, atypical mould infection, • Other OI based on exposures

  16. Hospital day 6 DWI ADC FLAIR

  17. EMERGING TRENDS IN INFECTION EMERGING TRENDS CHANGING OLD INFECTIONS NOVEL INFECTIONS Respiratory viruses Bacteria Fungus Viruses Vector borne viruses Blood/body fluid transmitted Enteric transmitted

  18. More potent immunosuppression Widespread prophylaxis KNOWN PATHOGEN • Modified presentation • Symptoms • Timing • Spectrum Drug resistance

  19. Aspergillus 9.4% Aspergillus Scedosporium Fusarium 30.2% Phaeohyphomycetes 9.4% Non-Aspergillus 69.8% 5.7% Zygomycetes 5.7% Other MOULD INFECTIONS in ORGAN TRANSPLANT RECIPIENTS Hyalohyphomycetes Husain et al. Clin Infect Dis 2003

  20. Gan, valgan, prophylaxis Potent Immunosuppression CMV • Modified presentation • Symptoms • Timing Drug resistance

  21. TIME to CMV DISEASE UP to 6 MONTHS (n=364) 100 90 364 D+/R- SOT patients 80 70 • May present with atypical symptoms (no fever – malaise, fatigue); diagnosis can be missed • Patient may not be followed by primary center or may not be followed as closely 60 50 % Patients with no CMV Disease 40 30 20 Prophylaxis period 10 0 0 10 20 30 40 50 60 70 80 90 100 110 120 130 140 150 160 170 180 190 200 Time (days) Paya et al. Am J Transplant 2004; 4: 611

  22. CMV RESISTANCE • Overall resistance rates low in most transplant populations • In certain subpopulations, resistance rates of up to 10% described in some studies • Especially lung transplant • Bharade et al. JHLT 2002, Limaye et al. JID 2002 • D+/R- lung recipients at highest risk • The two alternative therapies are • Foscarnet and cidofovir • Both have significant toxicities

  23. NOVEL INFECTIONS & TRANSPLANTATION Emerging Infections Old Pathogens Previouslyunrecognized Old Pathogens New disease (in transplant pts) New Pathogen New disease HHV-6/7 adenovirus BKVAN West Nile virus H1N1 influenza Xenotransplantion

  24. DWI ADC HHV-6 encephalitis Viral load 1.2 million copies/ml HHV-6 pneumonitis

  25. Clinical reactivation Subclinicalreactivation

  26. NEW PATHOGENS and the Transplant Patient 1. More likely to develop symptomatic disease if exposed to a pathogen 2. Once exposed, more rapidly progressive lethal disease ‘SENTINEL CHICKEN’ CONCEPT

  27. NEW PATHOGENS and the Transplant Patient 3. Higher viral burden – longer viral shedding with increased amounts of virus • Increased infectivity • Super-spreaders 4. Lack of response to therapeutic measures • Standard antiviral may have less efficacy • Decreased immunogenicity of vaccines

  28. EMERGING INFECTIONS AND TRANSPLANT • Transplant patients can potentially acquire a new pathogen in 3 ways: Transfusion- transmitted Community- acquired Organ- transmitted

  29. WNV and TRANSPLANTATION • Numerous case reports/series of TTWNV • High mortality (~ 30%) • Two instances of organ donor transmission of WNV (2003, 2005) • Most common is community acquired WNV • Immunocompetent : severe disease in 1:140

  30. 816 TRANSPLANT PATIENTS WNV IgG/IgM Seroprevalence study (0.25%; 95%CI 0.03-0.88%) Estimated risk of severe neuroinvasive disease 40% (95%CI 16-80%) Kumar D et al.Am J Transplant 2004; 4:1883

  31. Kumar/Humar Am J Transplant2005

  32. Pandemic (Novel) H1N1 virus • AST ID COP – 25 center study of epidemiology of H1N1 in transplantation (Kumar et al. ATC 2010)

  33. Figure 1: Time of onset of symptoms during the pandemic.

  34. Table 1: Demographics of solid organ transplant recipients with Influenza A BMI Body Mass Index

  35. Table 2: Clinical presentation and complications of Influenza A in adult and pediatric solid organ transplant recipients.

More Related